It may, therefore, be useful for other forms of HTG besides apoC-II deficiency and also for other CV diseases given the favorable results of clinical trials for Volanesorsen, an anti-sense oligonucleotide drug that blocks apoC-III production [129,130]. Here, APOC2 is linked to hyperinsulinemic hypoglycemia, familial, 4.